248 related articles for article (PubMed ID: 21992464)
21. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma.
Jeng YM; Wu MZ; Mao TL; Chang MH; Hsu HC
Cancer Lett; 2000 Apr; 152(1):45-51. PubMed ID: 10754205
[TBL] [Abstract][Full Text] [Related]
22. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex.
Jia D; Dong R; Jing Y; Xu D; Wang Q; Chen L; Li Q; Huang Y; Zhang Y; Zhang Z; Liu L; Zheng S; Xia Q; Wang H; Dong K; He X
Hepatology; 2014 Nov; 60(5):1686-96. PubMed ID: 24912477
[TBL] [Abstract][Full Text] [Related]
23. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
[TBL] [Abstract][Full Text] [Related]
24. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
25. Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
Zhou J; Liu X; Yin H; Zhou Y; Xu Z; Zhou K; Li T; Fang Y; Shen Q
Gene; 2024 May; 908():148292. PubMed ID: 38369247
[TBL] [Abstract][Full Text] [Related]
26. Upregulated YAP promotes oncogenic CTNNB1 expression contributing to molecular pathology of hepatoblastoma.
Lu S; Jiang M; Chen Q; Luo X; Cao Z; Huang H; Zheng M; Du J
Pediatr Blood Cancer; 2022 Sep; 69(9):e29705. PubMed ID: 35404538
[TBL] [Abstract][Full Text] [Related]
27. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.
Herynk MH; Tsan R; Radinsky R; Gallick GE
Clin Exp Metastasis; 2003; 20(4):291-300. PubMed ID: 12856716
[TBL] [Abstract][Full Text] [Related]
28. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
[TBL] [Abstract][Full Text] [Related]
29. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
[TBL] [Abstract][Full Text] [Related]
30. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
31. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
32. MAP kinase and beta-catenin signaling in HGF induced RPE migration.
Liou GI; Matragoon S; Samuel S; Behzadian MA; Tsai NT; Gu X; Roon P; Hunt DM; Hunt RC; Caldwell RB; Marcus DM
Mol Vis; 2002 Dec; 8():483-93. PubMed ID: 12500177
[TBL] [Abstract][Full Text] [Related]
33. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice.
Apte U; Zeng G; Muller P; Tan X; Micsenyi A; Cieply B; Dai C; Liu Y; Kaestner KH; Monga SP
Hepatology; 2006 Oct; 44(4):992-1002. PubMed ID: 17006939
[TBL] [Abstract][Full Text] [Related]
34. Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.
Náger M; Santacana M; Bhardwaj D; Valls J; Ferrer I; Nogués P; Cantí C; Herreros J
Cell Cycle; 2015; 14(22):3644-55. PubMed ID: 26654598
[TBL] [Abstract][Full Text] [Related]
35. Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma.
Kahana-Edwin S; McCowage G; Cain L; Saletta F; Yuksel A; Graf N; Karpelowsky J
Pediatr Blood Cancer; 2020 Nov; 67(11):e28594. PubMed ID: 32881242
[TBL] [Abstract][Full Text] [Related]
36. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte Growth Factor Modulates MET Receptor Tyrosine Kinase and β-Catenin Functional Interactions to Enhance Synapse Formation.
Xie Z; Eagleson KL; Wu HH; Levitt P
eNeuro; 2016; 3(4):. PubMed ID: 27595133
[TBL] [Abstract][Full Text] [Related]
38. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Perilongo G; Shafford E; Maibach R; Aronson D; Brugières L; Brock P; Childs M; Czauderna P; MacKinlay G; Otte JB; Pritchard J; Rondelli R; Scopinaro M; Staalman C; Plaschkes J;
Eur J Cancer; 2004 Feb; 40(3):411-21. PubMed ID: 14746860
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of molecular genetic alterations in hepatoblastoma.
von Schweinitz D; Kraus JA; Albrecht S; Koch A; Fuchs J; Pietsch T
Med Pediatr Oncol; 2002 Feb; 38(2):104-8. PubMed ID: 11813174
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
Schmidt A; Braeuning A; Ruck P; Seitz G; Armeanu-Ebinger S; Fuchs J; Warmann SW; Schwarz M
Toxicology; 2011 Mar; 281(1-3):7-14. PubMed ID: 21237236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
